Naseem Zojwalla

Naseem Zojwalla, M.D., joined Olema Oncology as Chief Medical Officer in January 2022, bringing more than 15 years of experience in oncology and clinical development within both the biopharmaceutical industry and academia. Prior to joining Olema, Dr. Zojwalla served as Vice President of Clinical Development at Turning Point Therapeutics and earlier at Peloton Therapeutics (acquired by Merck) where she headed clinical development and strategy leading to the first-in-class approval of Welireg® (belzutifan) for the treatment of VHL disease.